STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.

STERIS plc (NYSE:STE ) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer...

Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

STERIS plc (NYSE:STE ) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Of...

STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Str...

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

STE expects bioprocessing revenues to grow in the second half of fiscal 2025.

STERIS' strong prospects in the healthcare business bode well for investors.

I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted...

Steris (STE) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to earnings of $2.03 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte...

STE's strong prospects in the healthcare business arm bode well for investors.

DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 first quarter f...